The sale is small relative to market cap and likely part of routine option exercise and tax-related selling. Monitor for any subsequent Form 4 filings to confirm execution and any larger insider sales that may follow.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $64.69entry
- T+1 · 4d ago −2.04%α −1.68% · $63.37
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Harpreet S. Dhaliwal, an officer of Vaxcyte, filed a Form 144 notice of intent to sell 17,000 common shares with an estimated aggregate value of $1,153,101.50. The shares were acquired through the exercise of stock options on November 11, 2026, and the sale is planned for the open market via UBS Financial Services.
Key Facts
- Filer: Harpreet S. Dhaliwal, an officer of Vaxcyte, Inc.
- Shares to be sold: 17,000 shares of common stock
- Estimated aggregate value: $1,153,101.50
- Shares acquired via exercise of stock options on November 11, 2026
- Sale to be executed through UBS Financial Services, Inc.
- Filing date: November 12, 2026
Financial Impact
Sale of 17,000 shares valued at approximately $1.15 million, representing about 0.011% of Vaxcyte's $10.5B market cap.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- Insider selling could increase if additional officers file similar notices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001165 |
| Document: 0001969223-26-001165-index.html | 0001969223-26-001165 |
| Document: 0001969223-26-001165.txt | 0001969223-26-001165 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers